TWiV 1076: Clinical update with Dr. Daniel Griffin
- Author
- Vincent Racaniello
- Published
- Sat 06 Jan 2024
- Episode Link
- https://www.microbe.tv/twiv/twiv-1076/
In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Articles and graphs cited in TWIV CU 1076
- Global mpox circulation (WHO)
- Mpox in the Americas and Europe (CIDRAP)
- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- Influenza/flu surveillance (CDC)
- Influenza/flu map (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- Vaccine-Eligible Children Under-5 Years (PIDJ)
- Pre-school cohort vaccination rate (CIDRAP)
- Perinatal transmission and neonatal outcomes (IJID)
- Adverse maternal and neonatal effect (dgalerts)
- Ventilation home improvements (CDC)
- Quarantine/isolation guidelines (CDC)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma remmendation for immunocompromised (IDSociety)
- Corticosteroids in SARS-CoV-2
- Anticoagulation guidelines (hematology.org)
- Corticosteroids induced olfactory dysfunction (PLoS One)
- Convalescent Plasma Therapy: Long Term Implications (OFID)
- Preventing RSV infection by vaccination (MMWR)
- Antivirals and chronic kidney disease (CID) Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet Infectious Diseases)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV 1076
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
